deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05440786

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma

Sponsor: Eli Lilly and Company

Conditions Neoplasm Metastasis Sarcoma, Ewing
Interventions Abemaciclib Irinotecan Temozolomide
Updated 26 times since 2022 Last updated: Feb 20, 2026 Started: Sep 20, 2022 Primary completion: Jan 15, 2025 Completion: Sep 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neoplasm Metastasis and Sarcoma, Ewing, this trial is ongoing. The trial is conducted by Eli Lilly and Company and has accumulated 26 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Mar 2024 · 4 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Mar 2026 · 6 months · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

26 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE2

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 21 earlier versions

  1. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

  2. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  3. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  6. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  7. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  8. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE2

  9. Nov 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

  10. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  11. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  12. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  13. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  14. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  15. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  16. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  17. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  18. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  19. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  20. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  21. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Berlin, Germany , Bologna, Italy , Bordeaux, France , Chuo-ku, Japan , Esplugues de Llobregat, Spain , Essen, Germany , Freiburg im Breisgau, Germany , Fukuoka, Japan , Indianapolis, United States and 12 more locations